+

WO1999050289A2 - Genes associes a l'evolution des tumeurs et methodes d'utilisation - Google Patents

Genes associes a l'evolution des tumeurs et methodes d'utilisation Download PDF

Info

Publication number
WO1999050289A2
WO1999050289A2 PCT/US1999/007187 US9907187W WO9950289A2 WO 1999050289 A2 WO1999050289 A2 WO 1999050289A2 US 9907187 W US9907187 W US 9907187W WO 9950289 A2 WO9950289 A2 WO 9950289A2
Authority
WO
WIPO (PCT)
Prior art keywords
progression
polypeptide
expression
patient
cells
Prior art date
Application number
PCT/US1999/007187
Other languages
English (en)
Other versions
WO1999050289A3 (fr
Inventor
Nan Zhang
Paul B. Fisher
Original Assignee
Nan Zhang
Fisher Paul B
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nan Zhang, Fisher Paul B filed Critical Nan Zhang
Priority to AU34627/99A priority Critical patent/AU3462799A/en
Publication of WO1999050289A2 publication Critical patent/WO1999050289A2/fr
Publication of WO1999050289A3 publication Critical patent/WO1999050289A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • polypeptides may comprise one or more portions of a variant of an endogenous protein, where the portion is immunologically and/or biologically active (i.e., the portion exhibits one or more antigenic, immunogenic and/or biological properties characteristic of the full length protein).
  • a portion is at least as active as the full length protein within one or more assays to detect such properties.
  • a polypeptide "variant,” as used herein, is a polypeptide that differs from a native protein in substitutions, insertions, deletions and/or amino acid modifications, such that the antigenic, immunogenic and/or biological properties of the native protein are not substantially diminished.
  • a promoter or regulatory element thereof may be operatively linked to a reporter gene as described above.
  • a construct may be transfected into a suitable host cell, such as El 1-NMT or transfected forms of CREF Trans 6, including CREF-Trans 6:4NMT (expressing PTI-1), T24 (expressing ras), CREF-src (expressing src) and CREF- HPV (expressing HPV).
  • CREF-Trans 6:4NMT expressing PTI-1
  • T24 expressing ras
  • CREF-src expressing src
  • CREF- HPV expressing HPV
  • compositions comprise one or more such compounds and a physiologically acceptable carrier.
  • Certain vaccines may comprise one or more polypeptides and an immune response enhancer, such as an adjuvant or a liposome (into which the compound is incorporated).
  • Pharmaceutical compositions and vaccines may additionally contain a delivery system, such as biodegradable microspheres which are disclosed, for example, in U.S. Patent Nos. 4,897,268 and 5,075,109.
  • Pharmaceutical compositions and vaccines within the scope of the present invention may also contain other compounds, which may be biologically active or inactive.
  • cells may be protected from therapeutic damage (e.g., due to chemotherapy or a physical agent such as gamma-irradiation) and/or rendered resistant to progression by inhibiting or eliminating the expression and/or activity of a progression-related protein in the cells.
  • One preferred method for inhibiting the expression of a progression-related protein comprises providing an effective amount of antisense RNA in the cell.
  • antisense technology can generally be used to control gene expression through triple-helix formation, which compromises the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors or regulatory molecules (see Gee et al., In Huber and Carr, Molecular and Immunologic Approaches, Futura Publishing Co. (Mt. Kisco, NY; 1994).
  • Polypeptides, polynucleotides and antibodies, as described herein, may be used within a variety of methods for detecting a cancer, determining whether a cancer is in progression, and monitoring the progression and/or treatment of a cancer in a patient.
  • any of a variety of methods may be used to detect the activity or the level of a progression-related protein or mRNA in a sample.
  • Suitable biological samples include tumor or normal tissue biopsy, mastectomy, blood, lymph node, serum or urine samples, or other tissue, homogenate or extract thereof obtained from a patient.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des compositions et des méthodes destinées au diagnostic, au suivi et au traitement du cancer. Les composés de l'invention sont des protéines associées à l'évolution des tumeurs, des parties et des variantes desdites protéines, ainsi que des polynucléotides codant pour ces polypeptides, des anticorps fixant ces polypeptides et des agents modulant l'expression de ces polypeptides. L'invention concerne également des vaccins et des compositions pharmaceutiques renfermant de tels composés, lesquels vaccins et compositions peuvent être utilisés, par exemple, pour la prévention et le traitement du cancer. Les polypeptides peuvent également être utilisés comme marqueurs permettant de suivre la progression du cancer chez un patient.
PCT/US1999/007187 1998-03-31 1999-03-31 Genes associes a l'evolution des tumeurs et methodes d'utilisation WO1999050289A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU34627/99A AU3462799A (en) 1998-03-31 1999-03-31 Progression related genes and methods of use therefor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8019398P 1998-03-31 1998-03-31
US60/080,193 1998-03-31

Publications (2)

Publication Number Publication Date
WO1999050289A2 true WO1999050289A2 (fr) 1999-10-07
WO1999050289A3 WO1999050289A3 (fr) 2000-01-20

Family

ID=22155843

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/007187 WO1999050289A2 (fr) 1998-03-31 1999-03-31 Genes associes a l'evolution des tumeurs et methodes d'utilisation

Country Status (2)

Country Link
AU (1) AU3462799A (fr)
WO (1) WO1999050289A2 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU625169B2 (en) * 1987-03-23 1992-07-02 Imperial Chemical Industries Plc Molecular markers
US5085983A (en) * 1988-08-19 1992-02-04 City Of Hope Detection of human tumor progression and drug resistance
US5539096A (en) * 1994-09-08 1996-07-23 Universite De Montreal Genes differentially expressed in metastatic and non-metastatic rat rhabdomyosarcoma cell lines
US6146877A (en) * 1997-03-21 2000-11-14 The Trustees Of Columbia University In The City Of New York Identification of the progression elevated gene-3 and uses thereof

Also Published As

Publication number Publication date
WO1999050289A3 (fr) 2000-01-20
AU3462799A (en) 1999-10-18

Similar Documents

Publication Publication Date Title
US6887660B2 (en) Compounds for immunodiagnosis of prostate cancer and methods for their use
US6472520B2 (en) Rat PEG-3 promoter
CA2281952C (fr) Composes permettant l'immunotherapie du cancer de la prostate et procedes concernant leur utilisation
CA2742641A1 (fr) Composes permettant l'immunotherapie du cancer de la prostate et procedes concernant leur utilisation
AU3359295A (en) Lung cancer marker
JP2008043337A (ja) 乳癌の処置および診断のための組成物および方法
WO1999009166A2 (fr) Polypeptides de tumeur de la prostate et compositions antigenes
EP1127893A2 (fr) Compositions thérapeutiques et diagnostiques du carcinome mammaire et méthodes afférentes
WO1998042315A1 (fr) Identification du gene eleve de progression 3 et utilisations
EP0981613A1 (fr) Parg, proteine d'activation de gtpase exer ant une interaction avec ptpl1
JP4190291B2 (ja) 癌細胞の増殖を調節するのに有用なポリヌクレオチド
WO2000040752A2 (fr) Genes associes a des cancers et leurs produits
WO1999037775A2 (fr) Compositions et procedes pour la detection et le traitement du cancer du sein
WO1999050289A2 (fr) Genes associes a l'evolution des tumeurs et methodes d'utilisation
US6379951B1 (en) Compounds for immunotherapy of breast cancer and methods for their use
WO1997028193A9 (fr) Compositions et procedes utiles dans la detection et/ou le traitement d'etats cancereux
WO1997028193A1 (fr) Compositions et procedes utiles dans la detection et/ou le traitement d'etats cancereux
WO1999037776A1 (fr) Techniques de modulation de l'angiogenese
US7008772B1 (en) Compounds for immunodiagnosis of prostate cancer and methods for their use
WO1999054466A2 (fr) Antigenes associes au cancer du colon, et utilisations desdits antigenes a des fins diagnostiques ou therapeutiques
WO1999037774A2 (fr) Sequences associees a la differenciation cellulaire et procedes d'utilisation de ces sequences
WO1999037777A2 (fr) Sequences associees a une differentiation et methodes d'utilisation
WO1999060124A2 (fr) Sequences liees a la differenciation et procede d'utilisation correspondant
US7270980B2 (en) Compounds for immunodiagnosis of prostate cancer and methods for their use
CA2370482A1 (fr) Compositions et procedes utilises en therapie et dans le diagnostic de l'epithelioma malpighien spinocellulaire de la tete et du cou

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载